tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

CNTA Stock Latest News

Centessa 10.81M share Spot Secondary priced at $9.25
The FlyCentessa 10.81M share Spot Secondary priced at $9.25
3d ago
CNTA
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
PremiumPress Releases
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
3d ago
CNTA
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
PremiumPress Releases
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
3d ago
CNTA
Centessa announces $100M American Depositary Shares offering
PremiumThe Fly
Centessa announces $100M American Depositary Shares offering
3d ago
CNTA
Centessa Pharmaceuticals Advances Narcolepsy Drug Trials
PremiumCompany Announcements
Centessa Pharmaceuticals Advances Narcolepsy Drug Trials
5d ago
8K
CNTA
Centessa announces open IND for ORX750
PremiumThe FlyCentessa announces open IND for ORX750
5d ago
CNTA
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
PremiumPress Releases
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
5d ago
CNTA
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
PremiumPress Releases
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
29d ago
CNTA
Centessa reports Q4 EPS (38c), consensus (48c)
PremiumThe Fly
Centessa reports Q4 EPS (38c), consensus (48c)
29d ago
CNTA
CNTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CNTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
CNTA
Centessa Pharmaceuticals Unveils Clinical Data Online
PremiumCompany Announcements
Centessa Pharmaceuticals Unveils Clinical Data Online
3M ago
8K
CNTA
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
PremiumPress Releases
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
3M ago
CNTA
Centessa to present data from third year of Phase 2a study of SerpinPC
PremiumThe FlyCentessa to present data from third year of Phase 2a study of SerpinPC
3M ago
CNTA
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
PremiumPress Releases
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
5M ago
CNTA
Centessa announces Part 5 data from ongoing Phase 2a study of SerpinPC
PremiumThe Fly
Centessa announces Part 5 data from ongoing Phase 2a study of SerpinPC
5M ago
CNTA
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
PremiumPress Releases
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
5M ago
CNTA
Centessa’s (NASDAQ:CNTA) Narcolepsy Drug Wakes Up Investors
PremiumMarket News
Centessa’s (NASDAQ:CNTA) Narcolepsy Drug Wakes Up Investors
5M ago
CNTA
Centessa upgraded to Buy from Hold at Jefferies
PremiumThe Fly
Centessa upgraded to Buy from Hold at Jefferies
5M ago
CNTA
Centessa reports Q3 EPS (40c), consensus (52c)
PremiumThe Fly
Centessa reports Q3 EPS (40c), consensus (52c)
6M ago
CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
PremiumPress ReleasesCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
6M ago
CNTA
CNTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CNTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
6M ago
CNTA
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
PremiumPress Releases
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
6M ago
CNTA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >